By Fineline Cube 
Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced a strategic cooperation agreement with Delim Cosmetics & Pharma S.R.L., granting Bio‑Sincerity priority rights for Delim’s high‑value marketed products in Greater China. The initial collaboration focuses on innovative oral formulations of semaglutide, tirzepatide, and Minoxidil, covering full lifecycle from R&D through commercialization.
Partnership Structure & Strategic Terms
| Item | Detail |
|---|---|
| Partners | Bio‑Sincerity Pharma‑Tech (301096.SZ) / Delim Cosmetics & Pharma S.R.L. |
| Territory | Greater China – exclusive priority cooperation rights |
| Product Focus | Semaglutide, tirzepatide, Minoxidil (innovative oral formulations) |
| Scope | Research, development, production, and commercialization |
| Deal Type | Strategic cooperation agreement |
| Significance | Expands Bio‑Sincerity’s metabolic and dermatology pipeline with blockbuster‑caliber assets |
| Timeline | Initial phase targeting priority product development and regulatory filing |
Product Portfolio & Market Position
- Semaglutide: GLP‑1 receptor agonist for type 2 diabetes and obesity; oral formulation addresses injection‑averse patient segment
- Tirzepatide: Dual GIP/GLP‑1 agonist with superior weight‑loss efficacy; oral version would unlock massive China market potential
- Minoxidil: Topical hair‑loss treatment; innovative oral formulation targets androgenetic alopecia with improved patient compliance
- Strategic Rationale: Leverages Bio‑Sincerity’s CDMO expertise and Delim’s proprietary formulation technologies to create differentiated, patent‑protected oral products
Market Impact & Commercial Outlook
- China GLP‑1 Market: Projected to exceed ¥30 billion (US$4.2 billion) by 2028, driven by obesity epidemic and expanding reimbursement coverage
- Competitive Edge: Oral formulations of semaglutide and tirzepatide would be first‑in‑class in China, capturing premium pricing before injectable biosimilars saturate the market
- Revenue Potential: Analysts estimate ¥800 million–1.2 billion peak sales potential for the combined oral portfolio by 2030
- Manufacturing: Bio‑Sincerity’s GMP facilities in Hangzhou enable rapid scale‑up and cost‑competitive production for Greater China launch
- Next Steps: IND‑enabling studies for oral semaglutide slated to begin Q1 2026, with regulatory submission targeted for 2027
Forward‑Looking Statements
This brief contains forward‑looking statements regarding development timelines, regulatory approvals, and revenue projections for the oral formulation portfolio. Actual results may differ due to clinical trial outcomes, CDE review processes, and competitive dynamics in the metabolic disease market.-Fineline Info & Tech